Tags : Expansion


Intra-Cellular Reports the Expansion of Pipeline with the Addition of

Shots: Following the completion of a P-I program, the company plans to initiate P- II studies to evaluate ITI-1284 ODT-SL for the treatment of behavioral disturbances in dementia, dementia-related psychosis and certain depressive disorders in the elderly The P-I single and multiple ascending dose studies in healthy volunteers including elderly subjects aged >65yrs. evaluated the […]Read More


Novo Nordisk to Invest ~$117.4M in Expansion of its Production

Shots: Novo Nordisk to invest $117.4M in upgrading and expanding facilities at its production site in Kalundborg, Denmark The facilities currently develop diabetic therapies and will be rebuilt and expanded for the future production of these and the next generation of diabetic therapies. The projects are expected to be completed in 2022 The investment in […]Read More


Amgen Signs an Agreement with BeiGene for the Expansion of

Shots: Amgen acquires 20.5% stake in BeiGene for ~$2.8B in cash, with $174.85/share representing 36% premium. BeiGene will commercialize Xgeva, Kyprolis, and Blincyto in China with equal profit-loss sharing while two of them will revert to Amgen, after 5yrs. & 7yrs. BeiGene has the right to retain one product and will receive royalties on sales […]Read More


Mylan Launches Generic Faslodex Injection for the Expansion of its

Shots: Mylan launches Fulvestrant Injection (50 mg/mL)/single-dose prefilled syringe which is a generic version of AstraZeneca’s Faslodex Injection and has received FDA’s ANDA as monothx. for advanced BC in women with menopause and combination therapy for advance & m-BC The launch of Fulvestrant Injection expands Mylan’s oncology portfolio and available treatment options for women facing […]Read More


Jazz Pharmaceutical to Acquire Cavion for the Expansion of its

Shots: Jazz acquires Cavion, in all stock transaction making total deal value $312.5M. Cavion to receive $52.5M up front, ~$260M milestones based on certain clinical, regulatory and commercial activities The acquisition will broaden Jazz’s portfolio of sleep and neurological disorders and with the addition of Cavion’s CX-8998 it will further lead to expansion into movement […]Read More

M&A Pharma

STADA to Acquire GSK’s OTC Portfolio for the Expansion of

Shots: STADA acquires GSK’s six brands containing five skin care/topical application and one pediatric cough remedy namely Oilatum, Eurax, Savlon Antiseptic Cream, Ceridal, Tixylix and Polytar. The transaction is expected to close in Aug 2019 The focus of the acquisition is to strengthen and expand STADA’s Consumer Health business in European Healthcare markets. Additionally, the […]Read More